TLR9和NLRP3炎症组在急性胰腺炎中的作用

2011-08-03 MedSci原创 MedSci原创

来源:医学论坛网   近日,美国学者Rafaz Hoque等研究发现,急性胰腺炎的炎症形成需要Toll样受体9(TLR9)和炎症组(inflammasome)。相关研究发表在《胃肠病学》(Gastroenterology)杂志上。   急性胰腺炎,以继发于腺泡细胞死亡和炎症的、细胞内蛋白酶早期激活为特征。损害相关分子模式(DAMP)受体和一种胞质复合物的激活,一起被称为炎症组激活的炎症形式。该

来源:医学论坛网

  近日,美国学者Rafaz Hoque等研究发现,急性胰腺炎的炎症形成需要Toll样受体9(TLR9)和炎症组(inflammasome)。相关研究发表在《胃肠病学》(Gastroenterology)杂志上。

  急性胰腺炎,以继发于腺泡细胞死亡和炎症的、细胞内蛋白酶早期激活为特征。损害相关分子模式(DAMP)受体和一种胞质复合物的激活,一起被称为炎症组激活的炎症形式。该研究中,Rafaz Hoque等检测了DAMP受体和炎症组是否为细胞死亡与胰腺炎的炎症起始之间提供了联系。

  在野生型小鼠以及包含炎症组【包含一个蛋白酶募集域(ASC)的凋亡相关斑样蛋白、NLRP3、蛋白酶1】、Toll样受体9(TLR9),或嘌呤受体P2X7的缺陷小鼠中,由蛙皮素刺激诱导急性胰腺炎。在控制和蛙皮素治疗的成年鼠的胰腺中,停驻和浸润的免疫细胞群以及促白介素-1β的表达被标记。TLR9的表达在胰腺细胞群中被定量。此外,野生型小鼠在通过蛙皮素或逆行胆汁导管输注牛黄石胆酸3硫酸诱导急性胰腺炎前,被TLR9拮抗剂预处理。

  结果显示,急性胰腺炎中的炎症需要蛋白酶1、ASC和NLRP3。Tlr9的基因缺失,减低了胰腺炎中的胰腺水肿、炎症,和促白介素-1β的表达。TLR9表达于以巨噬细胞为主的胰腺停驻免疫细胞上。TLR9拮抗剂IRS954的预处理,减轻了胰腺水肿、炎性浸润,和凋亡。在牛黄石胆酸3硫酸诱导急性胰腺炎中,IRS954的预处理减轻了胰腺坏死和肺部炎症。

  因此,急性胰腺炎的炎症形成需要炎症组的成员ASC、蛋白酶1,和NLRP3的参与。TLR9和P2X7为重要的炎症组活化的上游DAMP受体,并且对它们的拮抗可能为治疗急性胰腺炎提供新的治疗策略。

相关链接:TLR9 and the NLRP3 Inflammasome Link Acinar Cell Death With Inflammation in Acute Pancreatitis

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746589, encodeId=47a51e4658956, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Thu Aug 25 20:38:00 CST 2011, time=2011-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407720, encodeId=62b3140e720db, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Fri Aug 05 08:38:00 CST 2011, time=2011-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538768, encodeId=2f721538e681e, content=<a href='/topic/show?id=93341286ee6' target=_blank style='color:#2F92EE;'>#NLRP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12867, encryptionId=93341286ee6, topicName=NLRP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=981f13051678, createdName=vera_1207, createdTime=Fri Aug 05 08:38:00 CST 2011, time=2011-08-05, status=1, ipAttribution=)]
    2011-08-25 lilianxiang
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746589, encodeId=47a51e4658956, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Thu Aug 25 20:38:00 CST 2011, time=2011-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407720, encodeId=62b3140e720db, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Fri Aug 05 08:38:00 CST 2011, time=2011-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538768, encodeId=2f721538e681e, content=<a href='/topic/show?id=93341286ee6' target=_blank style='color:#2F92EE;'>#NLRP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12867, encryptionId=93341286ee6, topicName=NLRP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=981f13051678, createdName=vera_1207, createdTime=Fri Aug 05 08:38:00 CST 2011, time=2011-08-05, status=1, ipAttribution=)]
    2011-08-05 yuandd
  3. [GetPortalCommentsPageByObjectIdResponse(id=1746589, encodeId=47a51e4658956, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd2d35803070, createdName=lilianxiang, createdTime=Thu Aug 25 20:38:00 CST 2011, time=2011-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407720, encodeId=62b3140e720db, content=<a href='/topic/show?id=a22412862b3' target=_blank style='color:#2F92EE;'>#NLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12862, encryptionId=a22412862b3, topicName=NLR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cd32710930, createdName=yuandd, createdTime=Fri Aug 05 08:38:00 CST 2011, time=2011-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538768, encodeId=2f721538e681e, content=<a href='/topic/show?id=93341286ee6' target=_blank style='color:#2F92EE;'>#NLRP3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12867, encryptionId=93341286ee6, topicName=NLRP3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=981f13051678, createdName=vera_1207, createdTime=Fri Aug 05 08:38:00 CST 2011, time=2011-08-05, status=1, ipAttribution=)]
    2011-08-05 vera_1207

相关资讯

利拉鲁肽胰腺炎和癌症危险

 6月13日,由于一项近期对医疗保健从业者的评估发现,一些初级保健从业者并未完全知晓胰高糖素样肽-1类似物利拉鲁肽相关的严重危险,因此诺和诺德公司通过美国FDA发布了重要的利拉鲁肽安全信息,提醒医生利拉鲁肽相关的胰腺炎和甲状腺C细胞肿瘤危险。   研究表明,在临床相关暴露剂量下,利拉鲁肽在大鼠和小鼠中,可引发剂量依赖性和治疗时间依赖性甲状腺C细胞肿瘤。目前,并不清楚利拉鲁肽是否在人体内也引发甲